---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174943"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:03:19.201333+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phathom Q2 revenue $39.5M, up from $7.3M YoY; 580k+ VOQUEZNA scripts filled

## Summary
- Net revenues $39.5M in Q2 2025 vs $7.3M in Q2 2024; net loss $75.8M vs $91.4M YoY.
- Over 580k total VOQUEZNA prescriptions filled (+49% since May 1); ~173k in Q2 (36% sequential growth).
- 10-year NCE exclusivity for VOQUEZNA 10mg/20mg tablets through May 2032; generic entry unlikely before 2033.
- Full-year 2025 revenue guidance $165M-$175M; expects non-GAAP OpEx <$60M in Q3 and <$55M in Q4.
- Appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary.

## SEC filing metadata
- accession: 0001193125-25-174943
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312525174943/0001193125-25-174943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312525174943/d907916d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174943
- JSON: https://secwatch.observer/filing/0001193125-25-174943.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174943.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.